Compare Cytokinetics Inc (CYTK) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Rush Street Interactive Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Rush Street Interactive Inc trades at $18.9 (market cap $2.35B). The key difference: Cytokinetics Inc is far larger — about 3.7× Rush Street Interactive Inc's market cap, and Cytokinetics Inc is more actively traded (2,594,626 versus 2,219,374). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Rush Street Interactive Inc for 13 Days on average.
| CYTK | RSI | |
|---|---|---|
Market Cap | $8.62B | $2.35B |
Volume | 2,594,626 | 2,219,374 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $34.52 |
52-Week Low | $54.76 | $15.89 |
Typical Hold Time | 19 Days | 13 Days |
Enterprise Value | $8.72B | $2.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Rush Street Interactive (RSI) trades at $20.32, up 0.4% on the day, with a bearish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates, and revenue growth from $1.13B in 2025 to $1.4B in 2026. Analyst consensus is bullish with a $34.88 price target, though net income margin compression from 2.93% to 2.33% highlights profitability challenges.
RSI presents a mixed outlook: robust revenue growth and solid analyst support contrast with thin margins and bearish technicals. The stock offers upside to consensus targets but faces execution risks in a competitive online betting market. Investors should weigh growth potential against margin pressures and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
